introduction
Targeted therapy describes treatment with agents that have a defined molecular target. The classic type of targeted therapy is the use of hormonal treatments in estrogen receptor (ER)-positive breast cancer (BC). The human epidermal growth factor receptor (HER/erbB) family of transmembrane receptors is also a target for novel agents that inhibit its activity. This receptor family includes epidermal growth factor receptor (EGFR), HER2, HER3 and HER4. Two classes of agents have been developed as inhibitors of the EGFR: the small-molecule tyrosine kinase inhibitors gefitinib and erlotinib and the mAbs cetuximab and panitumumab. The mAb trastuzumab inhibits the HER2 receptor, while the small-molecule lapatinib inhibits both the HER2 receptor and EGFR. Studies of gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) indicated disease response in an unselected group of patients varying from 10% to 20% with occasional patients having very long-lasting disease response [1, 2] .
EGFR is involved in the proliferation and metastases of tumors [3] . EGFR overexpression has been reported in primary BCs and appears to be associated with a poorer outcome. There is a correlation between EGFR expression and the absence of ERs in breast tumors. EGFR expression is also associated with resistance to hormonal therapy and a negative impact on disease-free survival [4] [5] [6] [7] [8] . Preclinical studies have indicated a potential role for gefitinib in the treatment of BC. In a series of experiments with MCF7 cells resistant to tamoxifen and the pure antiestrogen fulvestrant, increased dependence on EGFR signaling and sensitivity to gefitinib was demonstrated [9, 10] .
In the cells selected for resistance to tamoxifen, high levels of EGFR and HER2 were identified. Nicholson hypothesized that EGFR is part of a signaling network associated with either de novo or acquired antiestrogen resistance and that interruption of the signaling pathways might increase the efficacy of hormonal therapies in BC. In a preclinical model, gefitinib was shown to reverse tamoxifen resistance in HER2 receptor overexpressing hormone receptor (HR)-positive BC [11] . In a phase I trial of gefitinib in advanced solid tumors, stable disease (SD) for >3 months was observed in BC [12] .
This phase II clinical trial was planned to study whether disrupting tumor EGFR signaling with oral gefitinib in BC patients with either acquired or de novo resistance to antiestrogens was a beneficial strategy. The study was designed to assess if there was tumor shrinkage [complete response (CR, a complete response is the disappearance of all target lesions) or partial response (PR, a partial response is at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter)] or stability (clinical benefit) in patients with advanced breast cancer (ABC) with tumors that were secondarily resistant to antiestrogen treatment with both tamoxifen and an aromatase inhibitor or that were HR negative.
patients and methods
This study was conducted by Australian New Zealand Breast Cancer Trials Group and supported by AstraZeneca (1839IL/0067). The trial was conducted as a multicenter, open-label, noncomparative two-arm phase II trial of gefitinib monotherapy in two separate groups of patients with metastatic or inoperable locally ABC for whom chemotherapy was not indicated at that time. Group I comprised women with hormone-resistant HR-positive [ER+ and/or progesterone receptor positive (PgR+)] tumors who had tumor progression after treatment with both tamoxifen and an aromatase inhibitor. Group II comprised women with HR (ER2 and PgR2)-negative tumors.
Criteria for inclusion included written informed consent, cytologically or pathologically confirmed BC, female aged ‡18 years, metastatic or inoperable locally ABC, at least one measurable lesion as defined by RECIST criteria and a Karnofsky performance status of at least 60. Patients were excluded if they had received more than one previous chemotherapy regimen for advanced disease, if they had their last dose of systemic anticancer therapy within 21 days before the start of gefitinib treatment or if they had disease progression within 6 months of completion of adjuvant chemotherapy. They were also excluded if they were <2 weeks from completion of previous radiation therapy or had newly diagnosed cerebral metastases, other coexisting malignancies, an absolute neutrophil count of <1.5 · 10 9 /l, platelets <75 · 10 9 /l, a serum bilirubin >1.25· the upper limit of normal, an alanine aminotransferase or aspartate aminotransferase >2.5· the upper limit of normal or a serum creatinine >1.5· the upper limit of normal.
Treatment with gefitinib was administered continuously until disease progression, unacceptable toxicity or withdrawal of consent. The dose of gefitinib was 500 mg/day. Patients did not receive concurrent hormonal therapy with gefitinib. Dose interruption of gefitinib was utilized as the first approach to managing toxicity. If patients required a dose reduction due to toxicity, dose reduction from 500 to 250 mg/day was allowed. If a further dose reduction was indicated, then treatment was stopped and the patient withdrawn from the study. The National Cancer Institute-Common Toxicity Criteria (NCI-CTC) were used for the evaluation of toxic effects. For grade 3 or 4 skin toxicity, gefitinib was ceased for up to 14 days, until the rash resolved or improved to a grade 1 level. If clinically indicated, patients were allowed a dose reduction for continuation of therapy.
Clinical benefit was based on the RECIST criteria and patients were deemed to have clinical benefit if either the RECIST criteria for CR or PR were satisfied or SD was present for at least 24 weeks. Patients were evaluated before commencing therapy with a history, a physical examination, tumor assessment, a full blood examination, serum biochemistry for liver function and renal function, urine analysis and an ECG. Patients were assessed clinically every 28 days and radiological tumor assessments were conducted every 8 weeks until disease progression. Serum tumor markers CA 15-3 and carcinoembryonic antigen were measured every 8 weeks. Tumor slides or blocks were collected from the most recent pathological sample for each patient. These samples were sent to the DAKO laboratories in Copenhagen for EGFR analysis.
statistical methods
The trial comprised two separate phase II study groups designed to detect activity of gefitinib in patients with ABC. The phase II study for group I was in women with tumors that were HR positive, while the phase II study for group II was in women with tumors that were HR negative. The measure of treatment activity was clinical benefit (CR, PR or SD for at least 24 weeks). All patients enrolled who received gefitinib were considered in the intention to treat population. The two patient groups were analyzed separately without any formal comparisons drawn between them. Based on the planned sample size of 45 patients for each group, a clinical benefit rate of 20% would have a 95% confidence interval of 9.5% to 34.6%.
results
Sixty-six patients were entered into the study from July 2002 to August 2004. Forty patients were entered into group I (ERand/or PgR-positive hormone-resistant tumors) and 26 into group II (ER and PgR HR-negative tumors). One patient from group II did not commence treatment and is not included in the analyses. Two patients entered into group I did not meet full eligibility criteria as they had not received prior therapy with tamoxifen and/or an aromatase inhibitor but are included in the intent to treat analysis. The patient characteristics are detailed in Table 1 . The majority of patients were of good performance status (Karnofsky score ‡ 80%).
The results of treatment are reported in Table 2 . The median time to progression was 8 weeks in both groups. There was no tumor response, either complete or partial in either group of patients; however, two patients in the HR-negative group achieved SD for 24 weeks resulting in a clinical benefit rate in group II of 7.7% (95% CI 0.9% to 25.1%). Of these two patients, one received gefitinib for 24 weeks with SD, but subsequently ceased treatment due to skin toxicity. This patient had a transient 25% decline in serum CA 15-3 level after 8 weeks of therapy (from 109 to 81 U/ml), followed by a subsequent increase in CA 15-3 level to 50% higher than baseline at 24 weeks. This patient's tumor showed overexpression of both EGFR and HER2 and after ceasing gefitinib she was treated with trastuzumab therapy. The second patient received gefitinib for 40 weeks, when treatment was ceased due to progressive disease. In this patient, a serial rise in CA 15-3 level was noted during gefitinib therapy with levels of 49, 82 and 100 U/ml at baseline, 24 weeks and 40 weeks, respectively. This patient's tumor was triple negative in phenotype.
The trial was ceased prematurely because of the absence of CR or PR, and the low clinical benefit rate.
Toxicity was graded according to the CTC, Version 2.0 of the NCI and treatment-related toxicity is reported in Table 3 . A dose reduction to 250 mg/day was required in 20% of the patients and almost half of the patients had a dose interruption due to toxicity. Toxic effects experienced were similar to those previously reported with gefitinib. At the trial dose of 500 mg/ day, diarrhea and skin rash occurred in the majority of patients and nausea in about half of the patients. Grade 3 or 4 diarrhea occurred in 17% of the patients. Skin rash of grade 2 or higher occurred in 43% patients and in 12% of the patients, it was rated grade 3 or 4. No patients developed toxicity consistent with interstitial lung disease.
Of the 66 patients entered into the trial, 47 patients had their tumor samples tested for EGFR expression in an attempt to investigate the association between EGFR expression and disease control with gefitinib. However, due to the small number of patients achieving a clinical benefit, useful correlation was not identified.
discussion
The concept of targeted therapy where an agent inhibits a specific component of a vital biochemical pathway has been well demonstrated in BC where antiestrogens inhibit the estrogen-mediated biochemical pathways resulting in cell death. This has been translated into highly effective clinical therapies resulting in disease control in advanced disease and improved cure rates in women with early BC whose tumors express this target. The development of trastuzumab has confirmed the concept of developing highly specific agents against well-characterized targets. Profound improvements in disease-free and overall survival occur in those women with early BC with an amplification of the gene for the HER2 receptor [13, 14] .
Another member of the HER family of receptors, the EGFR is also involved in the proliferation and metastasis of tumors [3] . This pathway has been targeted by the small molecule, gefitinib (IressaÒ, AstraZeneca, Macclesfield, UK). While EGFR is overexpressed in 40%-80% of NSCLCs, gefitinib results in responses in only 10% of unselected previously treated patients. Adding gefitinib to platinum-based double chemotherapy for first-line treatment in patients with NSCLC did not enhance the response rate [15] . There was no correlation between the degree of immunohistochemical staining for EGFR of the lung tumors and the response to gefitinib. However, Lynch et al. [16] demonstrated that eight of Annals of Oncology original article nine patients whose tumors responded to gefitinib had gene mutations within the tyrosine kinase domain of EGFR. These mutations result in an increase in growth factor signaling and confer susceptibility to the inhibitor (gefitinib). Among seven lung cancer patients whose tumors did not respond to gefitinib, no such EGFR mutation was found. No similar EGFR mutation was detected when 15 BC-derived cell lines were tested. It has been reported that there appears to be a positive correlation between the development of skin toxicity (i.e. rash) during treatment with inhibitors of EGFR and the likelihood of tumor response [17] . In phase III trials testing erlotinib in NSCLC and pancreas cancer, the development of rash was correlated with overall survival and progression-free survival (PFS). In the lung cancer study, disease control (CR + PR + SD) was increased with the development of rash. With the 500 mg daily dose of gefitinib utilized in our BC trial, skin rash was frequent and 43% patients had skin rash of at least grade 2. This indicates that the lack of clinical benefit observed is unlikely to be attributable to inadequate drug concentration within the tumor.
There have been other phase II trials testing the efficacy of gefitinib 500 mg daily as monotherapy in patients with ABC with varying eligibility criteria and results. In a trial with no limit on prior therapies, Albain et al. [18] identified one PR and two patients with SD at 6 months among 63 patients (clinical benefit rate 4.8%). Similarly, Baselga et al. [19] treated patients with BC that was resistant to one or two prior chemotherapy regimens, with a tumor biopsy at baseline and after 4 weeks of therapy. Among 31 assessable patients treated with gefitinib, no response was observed, although three patients had SD for at least 6 months (clinical benefit rate 9.7%). Inhibition of EGFR phosphorylation was demonstrated but there was no effect on Ki67 in tumors. These results were thought to be consistent with a lack of EGFR dependence in the tested population. Von Minckwitz et al. [20] conducted a phase II trial of gefitinib in patients with anthracycline-and taxane-pretreated metastatic BC. Among 58 patients entered, one patient had a partial tumor response and was progression free at 6 months (1.7%). These three trials in heavily pretreated patients indicate a relatively low clinical benefit rate in this patient population. In our trial, patients were allowed prior adjuvant chemotherapy and a maximum of one prior chemotherapy regimen for advanced disease but were clinically selected with the aim of entering patients with tumors more likely to be dependent on EGFR signaling. A similarly low clinical benefit rate was observed in our trial.
One group has reported more encouraging preliminary results from their phase II trial of gefitinib in less heavily pretreated ABC [21] . They studied two groups of patients who had not received a prior anthracycline. The study groups comprised 27 patients with ER-positive tamoxifen-resistant disease and 27 patients with ER-negative disease. In the ERpositive cohort, there were several disease responses observed with a clinical benefit rate of 54.5%. In the ER-negative group, there was a clinical benefit rate of 20.8%. It was concluded that in the group of patients with ER-positive tamoxifenresistant tumors, gefitinib appeared to have significant activity. The ER-positive subgroup of patients studied by Agrawal et al. differs from that in our trial with regard to prior chemotherapy exposure and also in our trial, this patient subgroup had acquired resistance to both tamoxifen and an aromatase inhibitor.
In a presurgical study conducted by the Breast Cancer International Research Group (BCIRG) in women with primary invasive BC, patients were treated with gefitinib 250 mg daily for 14-45 days before surgery. Among 43 women with tumor biopsies evaluable for molecular analysis, 11 patients were categorized as exhibiting molecular growth inhibition, 10 patients showed molecular growth proliferation and 22 showed no significant change [22] . According to subtype, ER+PgR2 and HER2 amplified tumors defined a subgroup more likely to show molecular growth inhibition, while ER+PgR+ tumors were more likely to show molecular growth proliferation. Smith et al. conducted a preoperative study testing the combination of anastrozole and gefitinib in women with postmenopausal HRpositive primary BC. In a placebo-controlled randomized trial, 206 women received 16 weeks of therapy with anastrozole plus gefitinib 250 mg daily or anastrozole alone [23] . There was no evidence of benefit from the addition of gefitinib to neoadjuvant anastrozole. In this trial, there was a potential negative interaction between gefitinib and anastrozole in the subgroup of patients with ER+PgR+ tumors with clinical response rate of 48% for those receiving the combination of anastrozole plus gefitinib versus 72% for those receiving anastrozole alone, consistent with the molecular finding of the BCIRG study.
In another preoperative study in postmenopausal women, patients were required to have both ER-positive and EGFRpositive tumors. Fifty-six women were randomly assigned to receive the combination of gefitinib 250 mg/day plus anastrozole or placebo for a period of 4-6 weeks before surgery [24] . Patients assigned the combination of gefitinib and anastrozole had a greater reduction in proliferation as measured by Ki67 than those treated with gefitinib alone. Notably, tumor size as measured by ultrasonography showed a PR in about half the patients in each treatment group. The remaining patients had SD and disease progression occurred in none of the patients during treatment. This trial shows a potential role for gefitinib in untreated patients selected for EGFR expression in addition to ER expression.
Cristofanilli et al. [25] recently presented preliminary results of a double-blind randomized phase II trial comparing anastrozole combined with gefitinib with anastrozole plus placebo in postmenopausal women with HR-positive metastatic BC. Among 93 treated women, a marked PFS advantage was seen with the combination of anastrozole plus gefinitib 250 mg/day with a median PFS of 14.5 months compared with 8.2 months for anastrozole plus placebo (hazard ratio 0.55; 95% CI 0.32-0.94).
The EGFR inhibitor, erlotinib, has been evaluated in women with previously treated ABC. In a preliminary report of a phase II trial, one patient had a partial tumor response among a group of 43 patients who had received prior anthracycline, taxane and capecitabine therapy [26] . Among a separate group of 22 patients who had received at least one chemotherapy regimen for advanced disease, one patient had SD for 28 weeks. In a preoperative study of erlotinib administered for 6-14 days in 41 patients with untreated operable BC, inhibition of proliferation was observed in ER-positive BC, but not in HER2-positive or triple-negative BCs [27] . It was indicated that EGFR original article Annals of Oncology antagonists were worthy of testing in hormone-dependent tumors in combination with antiestrogens.
Data obtained from laboratory experiments with hormoneresistant breast cancer cells which over-expressed EGFR indicated that this hormone-resistant phenotype could be reversed by gefitinib in vitro. Our data do not support the role of single-agent gefitinib in previously treated women with ERand/or PgR-expressing hormone-resistant BCs that are resistant to tamoxifen and an aromatase inhibitor and in women with HR-negative tumors. Other trials in untreated primary BC or in women who have received tamoxifen as the only prior therapy have indicated that gefitinib may modulate tumor growth in some cases. Efforts to identify subtypes of HR-positive BC that might benefit from the combination of gefitinib plus hormonal therapy may be worthwhile as preclinical studies indicate this combination may delay the onset of hormone resistance. 
